Overview

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

Status:
RECRUITING

Trial end date:
2029-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to evaluate if an iodinated contrast medium sparing strategy using automated Carbon Dioxide (CO2) Injection prevents Major Adverse Kidney Events up to 90 days (MAKE90) in patients at moderately elevated risk for contrast-associated acute kidney injury (CA-AKI) undergoing infrainguinal peripheral vascular interventions (PVI).

Phase:

PHASE3

Details

Lead Sponsor:

University of Leipzig

Treatments:

Carbon Dioxide